

IN THE CLAIMS

Please replace claims 1, 11-12, 36, 39, and 44-45 with the following amended versions of the claims. For the Examiner's convenience, all pending claims are listed below.

1. (Once Amended) An isolated polypeptide selected from the group consisting of:

- A3
- a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2,
 - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2,
 - c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, and
 - d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

11. (Once Amended) An isolated antibody which specifically binds to a polypeptide selected from the group consisting of:

- A4
- a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2,
 - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2,
 - c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, and
 - d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

12. (Once Amended) An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4,
- b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90%

identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4,

- AY
- c) a polynucleotide complementary to a polynucleotide of a),
 - d) a polynucleotide complementary to a polynucleotide of b), and
 - e) an RNA equivalent of a)-d).

30. A diagnostic test for a condition or disease associated with the expression of PGAMP in a biological sample, the method comprising:

- a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and
- b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

31. The antibody of claim 11, wherein the antibody is:

- a) a chimeric antibody,
- b) a single chain antibody,
- c) a Fab fragment,
- d) a F(ab')₂ fragment, or
- e) a humanized antibody.

32. A composition comprising an antibody of claim 11 and an acceptable excipient.

33. A method of diagnosing a condition or disease associated with the expression of PGAMP in a subject, comprising administering to said subject an effective amount of the composition of claim 32.

34. A composition of claim 32, wherein the antibody is labeled.

35. A method of diagnosing a condition or disease associated with the expression of PGAMP in a subject, comprising administering to said subject an effective amount of the composition of claim 34.

36. (Once Amended) A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- AS
- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
 - b) isolating antibodies from said animal, and
 - c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

37. A polyclonal antibody produced by a method of claim 36.

38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

39. (Once Amended) A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- Alb
- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
 - b) isolating antibody producing cells from the animal,
 - c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
 - d) culturing the hybridoma cells, and
 - e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide

A6

having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

40. A monoclonal antibody produced by a method of claim 39.
41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.
42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.
43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant immunoglobulin library.

44. (Once Amended) A method of detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 in a sample, the method comprising:

A7

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 in the sample.

45. (Once Amended) A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 from a sample, the method comprising:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) separating the antibody from the sample and obtaining the purified polypeptide having

A7

an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.